Ligand Pharmaceuticals (LGND) Tax Expense: History & Chart

Ligand Pharmaceuticals Incorporated(LGND)

Biotechnology · Jupiter, FL

$296.94-9.83 (-3.20%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Jupiter, FL

47 employees

www.ligand.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Todd C. Davis

View full financials

Income Tax Expense

The latest quarterly tax expense is $15.80 Million. Income tax expense is the amount a company pays in federal, state, and foreign income taxes based on its taxable income for the period.

Q2 FY2026 (2026-06-30).

EBT|Net Income|Free Cash Flow|Revenue|Income Statement

Tax Expense

LGND Tax Expense

$15.80M

Reported quarterly tax expense; no daily interpolation. Q2 FY2026 (2026-06-30): $15.80M.

≈99x over 10Y

Current Tax Expense

$15.80M

$15.80 Million

Q2 FY2026 · 2026-06-30

QoQ Growth

N/A

Historical Data

Quarters of data available

Quarterly Tax Expense History

Period	Tax Expense	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$15.80M	N/A	+147.74%
Q1 FY2026Period end 2026-03-31	−$10.91M	N/A	-41.21%
Q4 FY2025Period end 2025-12-31	$12.00M	-49.73%	N/A
Q3 FY2025Period end 2025-09-30	$23.86M	+274.28%	+2764.83%
Q2 FY2025Period end 2025-06-30	$6.38M	N/A	N/A
Q1 FY2025Period end 2025-03-31	−$7.73M	+4.72%	N/A
Q4 FY2024Period end 2024-12-31	−$8.11M	N/A	-643.54%
Q3 FY2024Period end 2024-09-30	$833.00K	N/A	N/A
Q2 FY2024Period end 2024-06-30	−$13.48M	N/A	N/A
Q1 FY2024Period end 2024-03-31	$27.31M	N/A	+129.06%
Q4 FY2023Period end 2023-12-31	−$1.09M	+41.69%	N/A
Q3 FY2023Period end 2023-09-30	−$1.87M	N/A	N/A
Q2 FY2023Period end 2023-06-30	$881.00K	-92.61%	N/A
Q1 FY2023Period end 2023-03-31	$11.92M	-73.67%	+214.98%
Q4 FY2022Period end 2022-12-31	$45.27M	+1571.21%	N/A
Q3 FY2022Period end 2022-09-30	$2.71M	N/A	+76.37%
Q2 FY2022Period end 2022-06-30	−$3.94M	N/A	N/A
Q1 FY2022Period end 2022-03-31	$3.79M	N/A	N/A
Q4 FY2021Period end 2021-12-31	−$1.61M	N/A	+32.66%
Q3 FY2021Period end 2021-09-30	$1.54M	-40.37%	N/A
Q2 FY2021Period end 2021-06-30	$2.58M	N/A	-57.30%
Q1 FY2021Period end 2021-03-31	−$12.34M	-416.19%	-96.40%
Q4 FY2020Period end 2020-12-31	−$2.39M	+51.31%	-195.19%
Q3 FY2020Period end 2020-09-30	−$4.91M	N/A	-6.30%
Q2 FY2020Period end 2020-06-30	$6.03M	N/A	N/A
Q1 FY2020Period end 2020-03-31	−$6.28M	-675.80%	N/A
Q4 FY2019Period end 2019-12-31	−$810.00K	+82.47%	+94.34%
Q3 FY2019Period end 2019-09-30	−$4.62M	-28.01%	N/A
Q2 FY2019Period end 2019-06-30	−$3.61M	N/A	N/A
Q1 FY2019Period end 2019-03-31	$176.38M	N/A	+1657.96%
Q4 FY2018Period end 2018-12-31	−$14.31M	N/A	N/A
Q3 FY2018Period end 2018-09-30	$11.86M	-47.08%	+225.49%
Q2 FY2018Period end 2018-06-30	$22.42M	+123.45%	+899.96%
Q1 FY2018Period end 2018-03-31	$10.03M	-73.37%	+800.63%
Q4 FY2017Period end 2017-12-31	$37.67M	+933.61%	+263.83%
Q3 FY2017Period end 2017-09-30	$3.65M	+62.58%	N/A
Q2 FY2017Period end 2017-06-30	$2.24M	+101.26%	N/A
Q1 FY2017Period end 2017-03-31	$1.11M	-89.24%	-69.84%
Q4 FY2016Period end 2016-12-31	$10.36M	N/A	N/A
Q3 FY2016Period end 2016-09-30	$160.00K	N/A	N/A
Q2 FY2016Period end 2016-06-30	−$3.88M	N/A	N/A
Q1 FY2016Period end 2016-03-31	$3.69M	N/A	N/A
Q4 FY2015Period end 2015-12-31	−$515.00K	+99.76%	N/A
Q3 FY2015Period end 2015-09-30	−$217.25M	N/A	N/A
Q2 FY2015Period end 2015-06-30	$265.00K	N/A	N/A
Q1 FY2015Period end 2015-03-31	$15.00K	-94.62%	N/A
Q4 FY2014Period end 2014-12-31	$279.00K	N/A	N/A
Q3 FY2014Period end 2014-09-30	$124.00K	N/A	N/A
Q2 FY2014Period end 2014-06-30	−$47.00K	N/A	N/A
Q1 FY2014Period end 2014-03-31	$53.00K	N/A	N/A
Q4 FY2013Period end 2013-12-31	$139.00K	N/A	N/A
Q3 FY2013Period end 2013-09-30	$60.00K	N/A	N/A
Q2 FY2013Period end 2013-06-30	$110.00K	N/A	-67.46%
Q1 FY2013Period end 2013-03-31	$66.00K	N/A	N/A
Q4 FY2012Period end 2012-12-31	−$1.64M	N/A	N/A
Q3 FY2012Period end 2012-09-30	$142.00K	-57.99%	N/A
Q2 FY2012Period end 2012-06-30	$338.00K	N/A	N/A
Q1 FY2012Period end 2012-03-31	−$35.00K	N/A	+99.75%
Q4 FY2011Period end 2011-12-31	$495.00K	N/A	N/A
Q3 FY2011Period end 2011-09-30	$22.00K	N/A	-94.75%
Q2 FY2011Period end 2011-06-30	$141.00K	N/A	-77.44%
Q1 FY2011Period end 2011-03-31	−$13.78M	-250.14%	N/A
Q4 FY2010Period end 2010-12-31	−$3.94M	N/A	-156.35%
Q3 FY2010Period end 2010-09-30	$419.00K	-32.96%	N/A
Q2 FY2010Period end 2010-06-30	$625.00K	+128.10%	N/A
Q1 FY2010Period end 2010-03-31	$274.00K	N/A	N/A
Q4 FY2009Period end 2009-12-31	−$1.53M	N/A	N/A
Q3 FY2009Period end 2009-09-30	$0	N/A	-100.00%
Q2 FY2009Period end 2009-06-30	$0	N/A	N/A
Q1 FY2009Period end 2009-03-31	$0	N/A	N/A
Q4 FY2008Period end 2008-12-31	−$234.00K	N/A	+91.98%
Q3 FY2008Period end 2008-09-30	$2.99M	N/A	N/A
Q2 FY2008Period end 2008-06-30	−$1.03M	+42.17%	+75.62%
Q1 FY2008Period end 2008-03-31	−$1.78M	+38.97%	+80.63%
Q4 FY2007Period end 2007-12-31	−$2.92M	-23.64%	+91.92%
Q3 FY2007Period end 2007-09-30	−$2.36M	+44.14%	-185.02%
Q2 FY2007Period end 2007-06-30	−$4.22M	+54.05%	N/A
Q1 FY2007Period end 2007-03-31	−$9.19M	+74.55%	N/A
Q4 FY2006Period end 2006-12-31	−$36.12M	-4262.80%	N/A
Q3 FY2006Period end 2006-09-30	−$828.00K	N/A	N/A
Q2 FY2006Period end 2006-06-30	$18.00K	N/A	N/A
Q1 FY2006Period end 2006-03-31	$17.00K	N/A	N/A
Q4 FY2005Period end 2005-12-31	$5.00K	N/A	N/A
Q3 FY2005Period end 2005-09-30	$17.00K	N/A	-99.41%
Q2 FY2005Period end 2005-06-30	$17.00K	N/A	-99.42%
Q1 FY2005Period end 2005-03-31	$20.00K	N/A	-99.30%
Q4 FY2004Period end 2004-12-31	−$56.00K	N/A	+99.87%
Q3 FY2004Period end 2004-09-30	$2.90M	-1.59%	N/A
Q2 FY2004Period end 2004-06-30	$2.95M	+2.71%	N/A
Q1 FY2004Period end 2004-03-31	$2.87M	N/A	N/A
Q4 FY2003Period end 2003-12-31	−$43.40M	N/A	-67.79%
Q3 FY2003Period end 2003-09-30	$0	N/A	N/A
Q2 FY2003Period end 2003-06-30	$0	N/A	N/A
Q1 FY2003Period end 2003-03-31	$0	N/A	N/A
Q4 FY2002Period end 2002-12-31	−$25.87M	N/A	N/A
Q3 FY2002Period end 2002-09-30	$0	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.

Data as of June 30, 2026